Bicocca Open Archive

Logo unimib boa
PIAZZA, ROCCO GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 30.638
AS - Asia 16.082
EU - Europa 15.123
SA - Sud America 2.335
Continente sconosciuto - Info sul continente non disponibili 1.294
AF - Africa 388
OC - Oceania 36
Totale 65.896
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 29.205
SG - Singapore 5.529
IT - Italia 4.853
CN - Cina 3.329
DE - Germania 2.656
VN - Vietnam 2.552
HK - Hong Kong 1.865
RU - Federazione Russa 1.762
BR - Brasile 1.736
SE - Svezia 1.248
IE - Irlanda 1.206
CA - Canada 1.129
GB - Regno Unito 691
FR - Francia 602
UA - Ucraina 593
IN - India 490
BD - Bangladesh 446
FI - Finlandia 360
ID - Indonesia 284
KR - Corea 282
TR - Turchia 252
AR - Argentina 222
IQ - Iraq 178
ES - Italia 174
PL - Polonia 161
NL - Olanda 159
JP - Giappone 157
ZA - Sudafrica 149
MX - Messico 130
AT - Austria 129
CH - Svizzera 118
PK - Pakistan 109
SA - Arabia Saudita 105
DK - Danimarca 104
EC - Ecuador 91
CO - Colombia 85
BE - Belgio 79
VE - Venezuela 78
PH - Filippine 77
UZ - Uzbekistan 68
LT - Lituania 49
MA - Marocco 49
EG - Egitto 39
MY - Malesia 39
CL - Cile 37
JO - Giordania 35
KE - Kenya 32
BG - Bulgaria 31
CR - Costa Rica 31
PE - Perù 30
TN - Tunisia 30
AZ - Azerbaigian 29
CZ - Repubblica Ceca 29
AU - Australia 28
JM - Giamaica 28
NP - Nepal 26
IR - Iran 25
PY - Paraguay 25
TH - Thailandia 25
AE - Emirati Arabi Uniti 24
IL - Israele 24
ET - Etiopia 22
EU - Europa 22
DO - Repubblica Dominicana 21
BO - Bolivia 17
OM - Oman 17
AL - Albania 16
TT - Trinidad e Tobago 16
GR - Grecia 14
HN - Honduras 14
KZ - Kazakistan 14
PS - Palestinian Territory 14
RO - Romania 14
GT - Guatemala 13
KG - Kirghizistan 13
UY - Uruguay 13
NO - Norvegia 12
SV - El Salvador 12
LB - Libano 11
NI - Nicaragua 10
TW - Taiwan 9
DZ - Algeria 8
RS - Serbia 8
HU - Ungheria 7
LY - Libia 7
MU - Mauritius 7
AM - Armenia 6
GE - Georgia 6
LV - Lettonia 6
PA - Panama 6
PT - Portogallo 6
SN - Senegal 6
BB - Barbados 5
CI - Costa d'Avorio 5
CY - Cipro 5
EE - Estonia 5
MT - Malta 5
NG - Nigeria 5
NZ - Nuova Zelanda 5
PR - Porto Rico 5
Totale 64.515
Salva come PNG Salva come JPEG
Città #
Ann Arbor 4.898
Singapore 3.249
Ashburn 2.980
San Jose 1.976
Hong Kong 1.791
Milan 1.710
Frankfurt am Main 1.634
Woodbridge 1.226
Dublin 1.175
Chandler 1.067
Fairfield 965
Dallas 801
Houston 796
Ho Chi Minh City 764
Wilmington 750
Toronto 724
New York 702
Los Angeles 672
Hanoi 647
Jacksonville 542
Santa Clara 517
Beijing 511
Dearborn 507
Hefei 465
Chicago 458
Council Bluffs 456
Seattle 436
The Dalles 319
Princeton 310
Cambridge 307
Seoul 264
Shanghai 246
Boardman 229
Buffalo 217
Jakarta 217
Rome 217
Lauterbourg 211
São Paulo 209
Göttingen 205
Munich 176
Columbus 174
Moscow 172
Nanjing 168
Helsinki 153
Altamura 142
Orem 126
Montreal 124
Phoenix 123
Lawrence 121
Tokyo 114
London 113
Da Nang 109
Warsaw 108
Nuremberg 104
Atlanta 102
Denver 94
Guangzhou 94
Brooklyn 89
Turin 87
Kent 85
Lachine 85
San Diego 85
Chennai 80
Johannesburg 79
Haiphong 77
Stockholm 75
Brussels 74
Turku 72
Fürstenwalde 71
Naples 71
Staranzano 71
Zurich 70
Monza 69
Vienna 65
Baghdad 63
Romola 63
Fremont 60
Boston 57
Dong Ket 57
Washington 57
Poplar 56
Rio de Janeiro 56
Tashkent 56
Nanchang 55
Andover 54
Lissone 54
Ottawa 54
Tianjin 54
Shenyang 52
San Francisco 50
Desio 49
Dhaka 48
Ankara 47
Kocaeli 46
Riyadh 46
Hải Dương 44
Salt Lake City 44
Changsha 42
Biên Hòa 41
Can Tho 41
Totale 40.338
Salva come PNG Salva come JPEG
Nome #
Longitudinal cancer evolution from single cells 639
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways 638
Characterization of intra-host SARS-CoV-2 variants improves phylogenomic reconstruction and may reveal functionally convergent mutations 600
Personalized therapy design for liquid tumors via optimal control theory 576
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 569
VERSO: a comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples 552
A bioinformatics procedure to identify and annotate somatic mutations in whole-exome sequencing data 540
An Optimal Control Framework for the Automated Design of Personalized Cancer Treatments 508
ETNK1 mutations promote ROS production and DNA damage through increased mitochondrial activity 503
Variant calling from scRNA-seq data allows the assessment of cellular identity in patient-derived cell lines 496
OncoScore: A novel, Internet-based tool to assess the oncogenic potential of genes 486
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene 482
RNA-seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patients 471
Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study 471
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 469
ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine 463
LACE: Inference of cancer evolution models from longitudinal single-cell sequencing data 462
The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis 456
Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells 454
Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years 453
ETNK1 mutations in atypical chronic myeloid leukemia induce a mutator phenotype that can be reverted with phosphoethanolamine 448
Biallelic PI4KA Mutations Disrupt B-Cell Metabolism and Cause B-Cell Lymphopenia and Hypogammaglobulinemia 441
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub 439
ETNK1 MUTATIONS INCREASE MITOCHONDRIAL ACTIVITY AND PROMOTE DNA DAMAGE THROUGH ROS PRODUCTION 437
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 432
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 432
Absent B cells, agammaglobulinemia, and hypertrophic cardiomyopathy in folliculin-interacting protein 1 deficiency 431
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia 430
VERSO: a comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples 423
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 419
WHOLE-EXOME SEQUENCING OF A PHILADELPHIA NEGATIVE CHRONIC MYELOID LEUKEMIA PATIENT THROUGH THE EXON-CAPTURE TECHNIQUE 417
A computational procedure to identify and annotate somatic mutations in next-generation sequencing data 416
Idiopathic erythrocytosis: a germline disease? 413
Large-Scale Analysis of SARS-CoV-2 Synonymous Mutations Reveals the Adaptation to the Human Codon Usage During the Virus Evolution 412
Erratum: OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes 411
An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization 411
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 409
Hif1a: A putative modifier of hemochromatosis 405
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia 399
Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells 396
Integrative multi-omics analysis enables a comprehensive characterization of prostate cancer and unveils metastasis-associated candidate biomarkers 393
VirMutSig: Discovery and assignment of viral mutational signatures from sequencing data 390
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 389
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells 388
Imatinib long term effects study: three years of follow-up and assessment 388
Control-FREEC viewer: a tool for the visualization and exploration of copy number variation data 386
LACE 2.0: an interactive R tool for the inference and visualization of longitudinal cancer evolution 379
TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells 378
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib 375
Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies 370
Whole-Exome Sequencing Data - Identifying Somatic Mutations 368
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 366
Integrating mutational profiles and transcriptional data with ASTUTE to elucidate the key molecular functions involved in the pathogenesis of cancer 365
Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia 364
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling 356
A New BCR-ABL1 Mutation (L248R) Is Highly Resistant to Imatinib, Bosutinib, Nilotinib and Dasatinib, but Can Be Inhibited by AP-24534 and DCC-2036 354
Transcriptomic Profile of Human Osteoblast-like Cells Grown on Trabecular Titanium 352
Oncoscore, a Novel, Internet-Based Tool to Assess the Oncogenic Potential of Genes Can Differentiate Between CP-CML and BC-CML Associated Genes, and Between CP-CML Patients with Good and Bad Prognosis 348
Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients 348
Human chromosome 18 and acrocentrics: A dangerous liaison 348
Chronic myeloid leukemia: Second-line drugs of choice 347
Characterization of SARS-CoV-2 Mutational Signatures from 1.5+ Million Raw Sequencing Samples 346
Mutational signatures and heterogeneous host response revealed via large-scale characterization of SARS-CoV-2 genomic diversity 346
Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition 345
ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells 345
Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases 344
NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma 343
Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL) 343
Response to ‘D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients’ by leguay et al 342
Case Report: Successful use of emapalumab in adult B-cell acute lymphoblastic leukemia experiencing severe neurotoxicity and hemophagocytic lymphohistiocytosis-like features after CAR-T cell therapy 340
Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Differential Diagnosis in the WHO and ICC 2022 Era: A Focused Review 338
Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy 338
A fatal case of TEMPI syndrome, refractory to proteasome inhibitors and autologous stem cell transplantation 338
CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data 336
Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients 335
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants 335
Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex 333
Gene expression signature of non-involved lung tissue associated with survival in lung adenocarcinoma patients 330
Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia 327
Choosing the right TKI for chronic myeloid leukemia: when the truth lies in "long-term" safety and efficacy 327
Evidence for D276G and L364I Bcr-Abl mutations in Ph plus leukaemic cells obtained from patients resistant to Imatinib 326
BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients 325
Read-through transcripts in normal human lung parenchyma are down-regulated in lung adenocarcinoma 324
Integrated Analysis of Whole-Exome Sequencing and Micrornas Expression in Blast Crisis Transformation of Chronic Myeloid Leukemia 323
Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the Acute Myeloid Leukemia burden 320
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma 319
Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation 319
Early detection and improved genomic surveillance of SARS-CoV-2 variants from deep sequencing data 318
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients 313
Identification of a Novel Splicing Mutation in Blast Crisis Transformation of Chronic Myeloid Leukemia Integrating Whole-exome and RNA-Seq data 313
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias 309
Comprehensive analysis of mutational processes across 20 000 adult and pediatric tumors 308
Reply to P. Laneuville et al 308
ETNK1 is an early event and SETBP1 a late event in atypical Chronic Myeloid Leukemia 305
Characterization of cancer subtypes associated with clinical outcomes by multi-omics integrative clustering 303
In Vitro and in Vivo Characterization of Bosutinib as Substrate of the Pglycoprotein Efflux Transporter 302
DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients 300
Antibody Deficiency in Patients with Biallelic KARS1 Mutations 300
FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery 299
CML Patients Present Additional Mutations in Cancer Related Genes When Tested At Diagnosis 297
Totale 39.123
Salva come PNG Salva come JPEG
Categoria #
all - tutte 203.085
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 203.085
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.373 0 0 0 244 233 295 225 183 183 227 295 488
2022/20235.119 604 1.360 515 520 400 631 90 242 313 100 183 161
2023/20244.287 162 187 223 260 506 1.076 753 151 308 145 97 419
2024/20259.968 486 867 610 551 843 425 673 370 875 1.608 931 1.729
2025/202624.708 2.912 1.643 1.966 2.898 2.700 1.174 3.609 963 1.798 2.159 1.341 1.545
2026/20274.779 829 1.126 2.414 410 0 0 0 0 0 0 0 0
Totale 65.896